Success Metrics

Active Trials
1(10%)

Phase Distribution

Ph phase_3
2
20%
Ph phase_1
3
30%
Ph phase_2
5
50%

Phase Distribution

3

Early Stage

5

Mid Stage

2

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
3(30.0%)
Phase 2Efficacy & side effects
5(50.0%)
Phase 3Large-scale testing
2(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

10

all time

Status Distribution
Active(2)
Other(8)

Detailed Status

unknown8
Recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
1
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 13 (30.0%)
Phase 25 (50.0%)
Phase 32 (20.0%)

Trials by Status

recruiting110%
unknown880%
not_yet_recruiting110%

Recent Activity

1 active trials
Showing 5 of 10
recruitingphase_3

A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer

NCT05652894
not_yet_recruitingphase_1

MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinoma

NCT07054307
unknownphase_1

A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors

NCT04825392
unknownphase_1

A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma

NCT04756934
unknownphase_2

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

NCT04750083
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT05652894Phase 3

A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer

Recruiting
NCT07054307Phase 1

MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinoma

Not Yet Recruiting
NCT04825392Phase 1

A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors

Unknown
NCT04756934Phase 1

A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma

Unknown
NCT04750083Phase 2

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Unknown
NCT04749485Phase 2

A Study of HX008 for the Treatment of Patients With Malignant Melanoma

Unknown
NCT04741165Phase 2

Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)

Unknown
NCT04738630Phase 2

Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Unknown
NCT04486651Phase 3

HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer

Unknown
NCT04574817Phase 2

Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)

Unknown

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10